CBIO - Catalyst Biosciences, Inc.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.2246 |
| Open | 0.2300 |
| Bid | 0.2267 x 2900 |
| Ask | 0.2399 x 1300 |
| Day's Range | 0.2206 - 0.2399 |
| 52 Week Range | 0.1900 - 2.0900 |
| Volume | |
| Avg. Volume | 225,255 |
| Market Cap | 8.56M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | 1.03 |
| EPS (TTM) | 0.2200 |
| Earnings Date | Aug 14, 2023 - Aug 18, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 13, 2023 |
| 1y Target Est | N/A |
Fair Value
Related Research
Simply Wall St.Catalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 months
In the last year, multiple insiders have substantially increased their holdings of Catalyst Biosciences, Inc...
Insider Monkey12 Cheap Healthcare Stocks to Buy in 2023
In this piece, we will take a look at the twelve cheap healthcare stocks to buy in 2023. For more healthcare stocks, head on over to 5 Cheap Healthcare Stocks to Buy in 2023. The healthcare sector is one of the few industries that has rapidly transformed itself in just a couple of decades. Modern […]
GlobeNewswireCatalyst Biosciences Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the Company’s previously announced asset purchase agreement with GNI Group Ltd (“GNI Group”) and GNI Hong Kong Limited (together “GNI”) to purchase all of the assets and intellectual property rights primarily related to GNI’s proprietary hydronidone compound outside of China (collectively, the “F351 Assets”)
- GlobeNewswire
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21
- Simply Wall St.
Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)
Catalyst Biosciences ( NASDAQ:CBIO ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.88m (loss narrowed...
- Simply Wall St.
Bullish insiders at Catalyst Biosciences, Inc. (NASDAQ:CBIO) loaded up on US$1.2m of stock earlier this year
Over the last year, a good number of insiders have significantly increased their holdings in Catalyst Biosciences, Inc...
- GlobeNewswire
Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the rec
- GlobeNewswire
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend
- Simply Wall St.
Catalyst Biosciences (NASDAQ:CBIO) investors are sitting on a loss of 71% if they invested three years ago
Catalyst Biosciences, Inc. ( NASDAQ:CBIO ) shareholders will doubtless be very grateful to see the share price up 45...
- GlobeNewswire
Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation
Company to Announce a Record Date for Initial Distribution in Due CourseSOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s stockholders, has dismissed its lawsuits against the Company. “With the JDS1 litigation behind us, the Board of Directors will be meeting to determine the details of an initial distribution of capital, and we will communicate this inf
- GlobeNewswire
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022. “We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (“Vertex”) for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the
- Business Wire
JDS1, LLC Terminates Proxy Contest at Catalyst’s 2022 Annual Meeting
FORT LEE, N.J., August 11, 2022--JDS1, LLC ("JDS1"), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) ("Catalyst" or the "Company"), commented today on its previously announced withdrawal of the director nominations and other proposed business that it had intended to bring before the upcoming 2022 Annual Meeting of Stockholders of Catalyst Biosciences,
- GlobeNewswire
Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board
Encourages Stockholders to Vote on the WHITE Proxy CardSOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company,” “Catalyst” or “we”) announced that it has received a notice from JDS1, LLC (“JDS1”) that JDS1 has withdrawn the nominations of Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn (the “Withdrawn Candidates”) for election to the Catalyst Board of Directors at the Catalyst 2022 annual meeting of stockholders (the “2022 An
- GlobeNewswire
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company’s Nominees on the WHITE Proxy Card
ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan Catalyst Urges Stockholders to VOTE “FOR” All of the Company’s Nominees SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company,” “Catalyst” or “we”) today announced that leading proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis have recommended that Catalyst stockhold
- GlobeNewswire
Catalyst Biosciences Publishes New Investor Presentation
Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company Commits to Distributing $45 Million to Stockholders in an Initial Distribution, if Proxy Contest and Litigation End Soon, and Without Much Additional Expense Highlights the Concerning Connections Between JDS1’s Nominees and the Singer Family Stockholders Urged to VOTE “FOR” ALL of Catalyst’s Nominees, Who Are Committed to the Company’s Cash Distribution Plan, o
- GlobeNewswire
Catalyst Biosciences Announces Support from Largest Single Stockholder
JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst’s Nominees at the Company’s 2022 Annual Meeting Michael Torok from JEC Appointed as an Observer to the Transaction Committee of the Board of Directors Company Has Committed to Announcing a Record Date for a Substantial Distribution of Cash to Stockholders as Soon as Litigation and Proxy Fight are Resolved Catalyst Calls Upon JDS1 to Drop Its Litigation and Proxy Contest so the Company Can Expeditiously Execute Its Cash Distribut
- Business Wire
JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders
FORT LEE, N.J., July 22, 2022--JDS1, LLC, which collectively with the other participants in its solicitation beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) ("Catalyst" or the "Company"), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent a letter to its fellow stockholders. JDS1 is urging shareholders to vote on the GOLD proxy card to elect its slate of three
- GlobeNewswire
Catalyst Biosciences Sends Letter to Stockholders
Reiterates the Board’s Commitment to Expeditiously Distributing All of the Company’s Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior Motives in Running a Proxy Contest: Gaining Control of the Company’s Cash and Other Assets for JDS1’s Own Benefit Stockholders Urged to VOTE “FOR” ALL of Catalyst’s Nominees, Who Are Committed to the Company’s Cash Distribution Plan, on the WHITE Proxy Card SOUTH SAN FRANCISCO, Calif., July 19, 2022
ZacksHas Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Catalyst Biosciences, Inc. (CBIO) have performed compared to their sector so far this year.
- GlobeNewswire
Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling
Court Denies JDS1’s Motion for Expedited Proceedings Board Reiterates Commitment to Distributing Cash to Stockholders Once Potential Liability and Expenses Associated with Stockholder Litigation and Proxy Contest Are Known SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced that the Delaware Court of Chancery has denied the motion for expedited proceedings in the action brought by the plaintiff, JDS1, LL
- GlobeNewswire
Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain Assets and Extensive Engagement with Stockholders Board Will Set Initial Distribution Date and Amount Once Potential Liability and Expenses Associated with Stockholder Litigation and Proxy Contest Are Known SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its intention to
ZacksHas Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?
Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.